Company / Shareholders' Equity
Apellis Pharmaceuticals, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$370.1M
FY2025
5-year range
$169.9M / $370.1M
FY2021-FY2025
Trend
+62.0%
vs FY2024
Sector context
#113 of 213
Health Care
What the data says
At $370M, Apellis Pharmaceuticals, Inc.'s shareholders' equity ranks #113 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $170M in FY2022 to $370M in FY2025.
Based on SEC 10-K filings.
$370M in FY2025 with a 5-year CAGR of +12.6%.
Improved from $195M to $370M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +29.6%
- 5-Year CAGR
- +12.6%
- 10-Year CAGR
- -
Sector benchmark
#113 of 213 in Health CareTop 53% of 213This company $370.1M Sector average $2.5B
▼
-85.5% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +12.6%, indicating consistent growth.
- In FY2025, shareholders' equity increased 62.0% year-over-year.
- Ranks #113 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $370.1M | +62.0% |
| FY2024 | $228.5M | +17.5% |
| FY2023 | $194.5M | +14.5% |
| FY2022 | $169.9M | -14.5% |
| FY2021 | $198.7M | -2.9% |
| FY2020 | $204.6M | +497.6% |
| FY2019 | $34.2M | -78.7% |
| FY2018 | $161.0M | +8.1% |
| FY2017 | $148.9M | +526.0% |
| FY2016 | $23.8M | -32.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026